Edwards Lifesciences (EW) Other financing activities (2009 - 2026)

Edwards Lifesciences' Other financing activities history runs 18 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Other financing activities fell 96.59% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $125.9 million, a 45.17% decrease from a year earlier, with the FY2025 full-year figure at $174.1 million, down 3.01% from the prior year.
• Other financing activities retreated to $1.7 million in Q1 2026 per EW's latest filing, from $174.8 million in the prior quarter.
• Across five years, Other financing activities topped out at $182.7 million in Q4 2024 and bottomed at -$119.6 million in Q3 2024.
• The 5-year median for Other financing activities is $450000.0 (2022), against an average of $32.6 million.
• Across the five-year window, Other financing activities surged 33100.0% in 2023 and sank 187.24% in 2024, its largest moves.
• Year by year, Other financing activities stood at $100000.0 in 2022, then jumped by 33100.0% to $33.2 million in 2023, then jumped by 450.3% to $182.7 million in 2024, then fell by 4.32% to $174.8 million in 2025, then tumbled by 99.03% to $1.7 million in 2026.
• Per Business Quant, the three latest EW Other financing activities figures stand at $1.7 million (Q1 2026), $174.8 million (Q4 2025), and -$2.4 million (Q3 2025).